Advances in covalent kinase inhibitors

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Pharmacology

Background:

• Covalent kinase inhibitors (CKI) offer unique advantages over non-covalent drugs.
• CKIs irreversibly modify target proteins via electrophilic reactions with nucleophilic residues.
• The acrylamide warhead is prevalent in current CKI development and approved therapies.

Purpose of the Study:

• To provide a comprehensive review of CKIs reported between 2007 and 2018.
• To analyze the rationale behind electrophile (warhead) selection in CKI design.
• To highlight trends, optimization strategies, and FDA-approved CKIs.

Main Methods:

• Literature review of covalent kinase inhibitors from 2007-2018.
• Analysis of inhibitor design, warhead choice, and optimization approaches.
• Examination of FDA-approved covalent therapies and common themes in CKI data.

Main Results:

• The acrylamide group is the most common electrophile in CKIs.
• Significant research efforts are focused on characterizing alternative electrophiles for covalent inhibition.
• Analysis reveals common trends in CKI design and optimization strategies.

Conclusions:

• CKIs represent a significant and growing area in drug discovery.
• Understanding warhead selection and design principles is crucial for CKI development.
• The review provides insights into the evolution and future directions of covalent kinase inhibition.